Compare operating models before comparing suppliers. A patient-access programme, a pharmacy and a wholesaler perform different jobs. LillyDirect describes prescription fulfilment through dispensing pharmacies; NovoCare describes third-party providers supporting registration, dispensing and delivery. McKesson separately describes pharmaceutical distribution to settings including physician offices. These are not interchangeable purchasing arrangements. (lilly.com)
The following fit assessments are our recommended starting points, subject to the gates described later.
| Arrangement | What the clinic selects or purchases | When it fits | What to establish before selection |
|---|---|---|---|
| Manufacturer-linked branded access | A patient prescription and payment pathway | Self-pay cohorts where published programme terms and an external checkout fit the patient journey | Exact product eligibility, dispensing destination, ongoing price, status visibility and support ownership |
| Licensed pharmacy dispensing approved medicines | A dispensing relationship; potentially integration and support services | Mixed insurance/self-pay populations, multiple medicines, or requirements for negotiated operational reporting | Actual dispensing entities, payer participation, state permissions, product acceptance and service evidence |
| Authorised wholesale distribution for clinic stock | Medicine inventory and distribution services | A clinic with a defined, lawful stock-use model and the capability to manage inventory | Account and product eligibility, title transfer, storage, traceability, credit, returns and allocation |
| 503A patient-specific compounding | An individually assessed compounded prescription | A documented patient need that warrants a compliant compounding assessment—not routine price substitution | Prescription requirements, formulation-specific justification, copying restrictions, quality and state requirements |
| 503B outsourcing | An eligible compounded preparation, potentially for office stock | A specific outsourcing requirement that satisfies the applicable federal and state conditions | Actual preparation and ingredients, bulk-substance eligibility, copying restrictions, facility evidence and intended use |
| Prescription-routing technology | Software connecting prescribing and pharmacy workflows | A provider that needs pharmacy choice, exception handling or integration across partners | What the platform actually observes, which pharmacies are integrated, data portability and responsibilities |
The 503A/503B distinctions above derive from FDA's prescription guidance and statutory framework. The ability of an outsourcing facility to supply qualifying office stock does not establish permission to supply a particular compounded GLP-1 preparation. (fda.gov)
For an evidenced software example, Photon documents prescription routing, pharmacy search, fulfilment-status tracking and webhook updates. That establishes advertised technical capabilities, not pharmacy availability or a measured reduction in your clinic's workload. (photonhealth.com)
Explore the table row by row
A working view of the research
Manufacturer-linked branded access
- What the clinic selects or purchases
- A patient prescription and payment pathway
- When it fits
- Self-pay cohorts where published programme terms and an external checkout fit the patient journey
- What to establish before selection
- Exact product eligibility, dispensing destination, ongoing price, status visibility and support ownership
Sources cited on this page
- lilly.com · Source 1 ↗https://www.lilly.com/lillydirect/faq
- fda.gov · Source 2 ↗https://www.fda.gov/regulatory-information/search-fda-guidance-documents/prescription-requirement-under-section-503a-federal-food-drug-and-cosmetic-act-guidance-industry
- photonhealth.com · Source 3 ↗https://photonhealth.com/faq?utm_source=openai